Search

Your search keyword '"Nishanta Singh"' showing total 8 results
Start Over Author "Nishanta Singh" Topic medicine
8 results on '"Nishanta Singh"'

1. Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study

Author

Llewellyn Fleurs, Lydia Soto-Torres, Jared M. Baeten, Flavia Matovu Kiweewa, Patrick Ndase, Petina Musara, Ashley J Mayo, Nishanta Singh, Thesla Palanee-Phillips, Zakir Gaffoor, Daniel K. Gondwe, Morgan Garcia, Yvonne Makala, Krishnaveni Reddy, Neetha S. Morar, Nitesha Jeenarain, Leila E. Mansoor, Ellen Luecke, Doreen Kemigisha, Rachel Scheckter, Kubashni Woeber, Ariane van der Straten, and Kristine Torjesen

Subjects
medicine.medical_specialty, Anti-HIV Agents, Dapivirine, HIV prevention, HIV Infections, Phase (combat), symbols.namesake, Epidemiology, medicine, Humans, Poisson regression, Ring, business.industry, Public health, Research, Public Health, Environmental and Occupational Health, Attendance, Contraceptive Devices, Female, food and beverages, Vaginal ring, Participant engagement, PrEP, Microbicides, Pyrimidines, Adherence, Family medicine, symbols, Female, Biostatistics, Public aspects of medicine, RA1-1270, business
Abstract

Background Low adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies, efforts are needed to improve adherence among study participants. In MTN-020/ASPIRE, a phase III randomized, double-blind, placebo-controlled study of the dapivirine vaginal ring carried out across 15 sites in sub-Saharan Africa, a multifaceted approach to adherence support was implemented, including a strong focus on participant engagement activities (PEAs). In this manuscript, we describe PEAs and participant attendance, and analyze the potential impact of PEAs on ring use. Methods All sites implemented PEAs and submitted activity and attendance reports to the study management team throughout the study. Participant demographics were collected via case report forms. Residual dapivirine remaining in the last ring returned by each participant was used to estimate drug released from the ring, which was then adjusted for time participants had the ring to calculate probable use categorized into three levels (low/intermittent/high). Product use was connected to PEA attendance using participant identification numbers. We used multivariate Poisson regression with robust standard errors to explore differences in ring use between PEA attendance groups and reviewed qualitative reports for illustrative quotes highlighting participant experiences with PEAs. Results 2312 of 2629 study participants attended at least one of 389 PEAs conducted across sites. Participant country and partner knowledge of study participation were most strongly associated with PEA attendance (p p Conclusions Our analysis supports the growing body of work illustrating the importance of meaningfully engaging research participants to achieve study success and aligns with other analyses of adherence support efforts during ASPIRE. While causation between PEA attendance and product use cannot be established, residual drug levels in returned rings strongly correlated with participant attendance at PEAs, and the benefits of incorporating PEAs should be considered when designing future studies of investigational products.

Published
2021

2. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

Author

Federica Cappuccini, P Cicconi, M Pace, Susanna Dunachie, Nishanta Singh, Catherine M. Green, Eleanor Barnes, Matthew Jones, J Fowler, Sarah C. Gilbert, N G Marchevsky, T Tipoe, C Fairhead, Yama F Mujadidi, M A Ansari, Teresa Lambe, S Serrano, P Goulder, P Zacharopoulou, S Broadhead, S Adele, F Ryan, Katie J. Ewer, L Parolini, Simon Kerridge, D Jenkin, Cooney E, Anele Waters, Christina Dold, Hill Avs., Parvinder K. Aley, Anthony Brown, Alison M. Lawrie, R Song, Paul Klenerman, Alexander D. Douglas, M Bittaye, M N Ramasamy, John Frater, Sarah Fidler, H Fok, Hannah Robinson, Mohammed K. Ali, Emily Adland, Angela M. Minassian, Julie Fox, Wanwisa Dejnirattisai, P M Folegatti, P Rongkard, C Petersen, Harriet R. Brown, Elizabeth A. Clutterbuck, Watson Mee., C Gibbs, N Robinson, Merryn Voysey, Emma Plested, J Alagaratnam, A Ogbe, S Bibi, A Bara, Alissa Goodman, Alan Winston, R Makinson, H Nguyen, Andrew J. Pollard, Gavin R. Screaton, S Rhead, Katrina M Pollock, Group, Oxford COVID Vaccine Trial, Imperial College Healthcare NHS Trust- BRC Funding, and Medical Research Council (MRC)

Subjects
Adult, Male, 0301 basic medicine, medicine.medical_specialty, COVID-19 Vaccines, Epidemiology, Immunology, Population, HIV Infections, Antibodies, Viral, 03 medical and health sciences, 0302 clinical medicine, Oxford COVID Vaccine Trial Group, ChAdOx1 nCoV-19, Virology, Internal medicine, medicine, Humans, 030212 general & internal medicine, education, Adverse effect, 11 Medical and Health Sciences, education.field_of_study, SARS-CoV-2, business.industry, Immunogenicity, Comment, Vaccination, COVID-19, Articles, Middle Aged, 030112 virology, CD4 Lymphocyte Count, Clinical trial, Infectious Diseases, Clinical research, Chills, medicine.symptom, business, Viral load
Abstract

Background: data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40 million people globally living with HIV who might have less functional immunity and more associated comorbidities than the general population. We aimed to explore safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV. Methods: in this single-arm open-label vaccination substudy within the protocol of the larger phase 2/3 trial COV002, adults aged 18–55 years with HIV were enrolled at two HIV clinics in London, UK. Eligible participants were required to be on antiretroviral therapy (ART), with undetectable plasma HIV viral loads (0·05 for all analyses). Interpretation: in this study of people with HIV, ChAdOx1 nCoV-19 was safe and immunogenic, supporting vaccination for those well controlled on ART. Funding: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca.

Published
2021
Full Text
View/download PDF

3. Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

Author

Leon Fouche, Greg Glenn, Susan Neal, Chijioke Bennett, Anthonet Koen, Tulio de Oliveira, Andreana Robertson, Asha Thombrayil, Natasha Lalloo, Lee Fairlie, Gary Albert, Iksung Cho, Mingzhu Zhu, Aylin Oommen-Jose, Zaheer Hoosain, Lou Fries, Sherika Hanley, Vicky L Baillie, Moherndran Archary, As'Ad E. Bhorat, Michele Tameris, Aliasgar Esmail, Pieter Louis Vollgraaff, Shabir A. Madhi, Filip Dubovsky, Sutika Bhikha, Friedrich G. Petrick, Annah Pitsi, Sharne Foulkes, Nazira Carrim-Ganey, Keertan Dheda, Ameena Ebrahim Goga, Gertruida Kruger, Angelique Kany Kany Luabeya, Joyce S. Plested, Dhayendre Moodley, Emmanuel Faust, Nishanta Singh, Q E Bhorat, Coert Grobbelaar, Shane Cloney-Clark, Umesh G. Lalloo, Johan Lombaard, Vivek Shinde, Mduduzi Masilela, Khatija Ahmed, Gabriella Benade, Cheryl Louw, and Rosie Mngqibisa

Subjects
Adult, 2019-20 coronavirus outbreak, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Adolescent, viruses, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 030204 cardiovascular system & hematology, Article, COVID-19 Serological Testing, 03 medical and health sciences, South Africa, Young Adult, 0302 clinical medicine, Immunogenicity, Vaccine, Double-Blind Method, HIV Seronegativity, Pandemic, HIV Seropositivity, Medicine, Humans, 030212 general & internal medicine, Adverse effect, Aged, Aged, 80 and over, biology, business.industry, SARS-CoV-2, Immunogenicity, virus diseases, COVID-19, General Medicine, Middle Aged, Virology, Antibodies, Neutralizing, Multicenter study, biology.protein, Antibody, business
Abstract

BACKGROUND: The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the coronavirus disease 2019 (Covid-19) pandemic. In a phase 1-2 trial involving healthy adults, the NVX-CoV2373 nanoparticle vaccine had an acceptable safety profile and was associated with strong neutralizing-antibody and antigen-specific polyfunctional CD4+ T-cell responses. Evaluation of vaccine efficacy was needed in a setting of ongoing SARS-CoV-2 transmission. METHODS: In this phase 2a-b trial in South Africa, we randomly assigned human immunodeficiency virus (HIV)-negative adults between the ages of 18 and 84 years or medically stable HIV-positive participants between the ages of 18 and 64 years in a 1:1 ratio to receive two doses of either the NVX-CoV2373 vaccine (5 μg of recombinant spike protein with 50 μg of Matrix-M1 adjuvant) or placebo. The primary end points were safety and vaccine efficacy against laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants without previous SARS-CoV-2 infection. RESULTS: Of 6324 participants who underwent screening, 4387 received at least one injection of vaccine or placebo. Approximately 30% of the participants were seropositive for SARS-CoV-2 at baseline. Among 2684 baseline seronegative participants (94% HIV-negative and 6% HIV-positive), predominantly mild-to-moderate Covid-19 developed in 15 participants in the vaccine group and in 29 in the placebo group (vaccine efficacy, 49.4%; 95% confidence interval [CI], 6.1 to 72.8). Vaccine efficacy among HIV-negative participants was 60.1% (95% CI, 19.9 to 80.1). Of 41 sequenced isolates, 38 (92.7%) were the B.1.351 variant. Post hoc vaccine efficacy against B.1.351 was 51.0% (95% CI, -0.6 to 76.2) among the HIV-negative participants. Preliminary local and systemic reactogenicity events were more common in the vaccine group; serious adverse events were rare in both groups. CONCLUSIONS: The NVX-CoV2373 vaccine was efficacious in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant. (Funded by Novavax and the Bill and Melinda Gates Foundation; ClinicalTrials.gov number, NCT04533399.).

Published
2021

4. Impact of Male Partner Involvement on Women’s Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial

Author

Gonasagrie Nair, Jared M. Baeten, Thesla Palanee-Philips, Kalendri Naidoo, Nishanta Singh, Sarah T. Roberts, Elizabeth T. Montgomery, Zakir Gaffoor, Vaneshree Govender, Samuel Kabwigu, Katie Schwartz, Krishnaveni Reddy, Aspire Study Team, Flavia Matovu Kiweewa, and Samantha Siva

Subjects
Adult, Male, Zimbabwe, Malawi, medicine.medical_specialty, Adolescent, Social Psychology, Anti-HIV Agents, Dapivirine, Psychological intervention, HIV Infections, Article, South Africa, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Humans, Medicine, Uganda, 030212 general & internal medicine, 030505 public health, business.industry, Vaginal microbicide, Public health, Public Health, Environmental and Occupational Health, Attendance, Contraceptive Devices, Female, Vaginal ring, Microbicides for sexually transmitted diseases, Health psychology, Pyrimidines, Infectious Diseases, Family medicine, Female, 0305 other medical science, business
Abstract

Although vaginal microbicides for HIV prevention are designed to be female-initiated, male partner influence has been identified as one of the most significant factors impacting women's willingness and ability to use them. As a result, research teams have sought to increase male partner involvement by encouraging disclosure of product use to male partners, promoting male partner engagement in the study through attendance at the study clinic, and helping women to garner male partner support for product use. This paper aims to assess the impact of these three elements of male partner involvement on women's adherence to the dapivirine vaginal ring during MTN-020/ASPIRE, a phase III randomized placebo-controlled clinical trial involving 2629 women in Malawi, South Africa, Uganda, and Zimbabwe. During the study, 64-80% of participants reported disclosure of ring use at each quarterly visit, and 13% reported that their partners had attended the study clinic at some point during the study. At study exit, 66% reported that their partner was supportive, 18% unsupportive, and 17% were unsure. After adjusting for age, site and time in study, women were more likely to have low ring adherence if they had an unsupportive male partner (aRR 1.29, 95% CI 1.03-1.62). Neither disclosure nor clinic attendance directly predicted ring adherence, but disclosure increased the probability of having a supportive partner (aRRR 24.17, 95% CI 16.38-35.66) or an unsupportive partner (aRRR 4.10, 95% CI 2.70-6.24), relative to an unknown level of partner support. Women were also more likely to have a supportive partner if their partner had attended the clinic (aRRR 3.77, 95% CI 1.36-10.42). This study suggests that although the vaginal ring is relatively discreet, lack of support from male partners remains a relevant barrier to use. Though both disclosure and clinic attendance may increase partner support, disclosure may also increase partner opposition. Interventions to reduce male partner opposition are needed to maximize the potential impact of the ring and other PrEP products for HIV prevention.

Published
2019
Full Text
View/download PDF

5. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults

Author

Philip Kotze, Fatima Laher, Mary Allen, Peter B. Gilbert, Jia J. Kee, Dishiki Jenny Kalonji, Carter Bentley, Susan W. Barnett, Tricia Philip, Craig Innes, Adrian Puren, Holly Janes, Millicent Atujuna, Nivashnee Naicker, M. Juliana McElrath, Philisiwe B. Makhoba, Gladys Kobane, Girisha Kistnasami, Katlego S. Mapetla, Zakir Gaffoor, Cleon N. Ncayiya, Sanjay Phogat, Vimla Naicker, Simbarashe Takuva, James G. Kublin, Linda-Gail Bekker, Nima S. Hejazi, David Benkeser, Niranjan Kanesa-thasan, Modulakgotla Sebe, Olivier Van Der Meeren, Yunda Huang, Bontle Modibedi, Pamela Mda, Mookho Malahleha, Mpho Sikhosana, Matsontso Mathebula, Pearl Selepe, Amy Ward, Lawrence Corey, Megan Jones, John Hural, Tania Adonis, Sheetal Kassim, Carlos Diaz Granados, Nicole Grunenberg, Shelly Ramirez, Doug Grove, Maphoshane Nchabeleng, Brittany Prigmore, Graeme Meintjes, Erica Lazarus, William Brumskine, Lubbe Wiesner, Nigel Garrett, Marguerite Koutsoukos, Thozama Dubula, Zoe Moodie, Glenda Gray, Nishanta Singh, and Michele P. Andrasik

Subjects
Adult, Male, Squalene, medicine.medical_specialty, Adolescent, Population, Genetic Vectors, Immunization, Secondary, Polysorbates, HIV Infections, 030204 cardiovascular system & hematology, Canarypox virus, law.invention, 03 medical and health sciences, South Africa, Young Adult, 0302 clinical medicine, Immunogenicity, Vaccine, Randomized controlled trial, Adjuvants, Immunologic, Double-Blind Method, law, Internal medicine, medicine, Humans, 030212 general & internal medicine, Treatment Failure, HIV vaccine, education, AIDS Vaccines, education.field_of_study, business.industry, General Medicine, Interim analysis, Vaccine efficacy, Vaccination, Regimen, AIDSVAX, HIV-1, Female, business
Abstract

Background A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous regimen using HIV-1 subtype C virus showed potent humoral and cellular responses in a phase 1-2a trial in South Africa. Efficacy data and additional safety data were needed for this regimen in a larger population in South Africa. Methods In this phase 2b-3 trial, we randomly assigned 5404 adults without HIV-1 infection to receive the vaccine (2704 participants) or placebo (2700 participants). The vaccine regimen consisted of injections of ALVAC-HIV at months 0 and 1, followed by four booster injections of ALVAC-HIV plus bivalent subtype C gp120-MF59 adjuvant at months 3, 6, 12, and 18. The primary efficacy outcome was the occurrence of HIV-1 infection from randomization to 24 months. Results In January 2020, prespecified criteria for nonefficacy were met at an interim analysis; further vaccinations were subsequently halted. The median age of the trial participants was 24 years; 70% of the participants were women. The incidence of adverse events was similar in the vaccine and placebo groups. During the 24-month follow-up, HIV-1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group (hazard ratio, 1.02; 95% confidence interval, 0.81 to 1.30; P = 0.84). Conclusions The ALVAC-gp120 regimen did not prevent HIV-1 infection among participants in South Africa despite previous evidence of immunogenicity. (HVTN 702 ClinicalTrials.gov number, NCT02968849.).

Published
2021

6. Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

Author

Mduduzi Lawrance Sandile Masilela, Sherika Hanley, Asha Thombrayil, As’ad E. Bhorat, Nazira Carrim-Ganey, Sutika Bhikha, Natasha Lalloo, Gary Albert, Filip Dubovsky, Mingzhu Zhu, Dhayendre Moodley, Friedrich G. Petrick, Gregory M. Glenn, Tulio de Oliveira, Vicky L Baillie, Joyce S. Plested, Emmanuel Faust, Lee Fairlie, Zaheer Hossain, Jonah J Lombaard, Shane Cloney-Clark, Aylin Oommen Jose, Umesh G. Lalloo, Shabir A. Madhi, Lou Fries, Moherndran Archary, Ameena Ebrahim Goga, Leon Fouche, Andreana Robertson, Gertruida Kruger, Coert Grobbelaar, Pieter-Louis Vollgraaff, Susan Neal, Anthonet Koen, Annah Pitsi, Sharne Foulkes, Angelique Kany Kany Luabeya, Iksung Cho, Aliasgar Esmail, Chijioke Bennett, Michele Tameris, Cheryl Louw, Rosie Mngqibisa, Nishanta Singh, Q E Bhorat, Keertan Dheda, Khatija Ahmed, Gabriella Benade, and Vivek Shinde

Subjects
medicine.medical_specialty, Reactogenicity, business.industry, medicine.medical_treatment, Incidence (epidemiology), Placebo, Vaccine efficacy, Internal medicine, medicine, Clinical endpoint, Adverse effect, Serostatus, business, Adjuvant
Abstract

BackgroundThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens progress toward control of the Covid-19 pandemic. Evaluation of Covid-19 vaccine efficacy against SARS-CoV-2 variants is urgently needed to inform vaccine development and use.MethodsIn this phase 2a/b, multicenter, randomized, observer-blinded, placebo-controlled trial in South Africa, healthy human immunodeficiency virus (HIV)-negative adults (18 to 84 years) or medically stable people living with HIV (PLWH) (18 to 84 years) were randomized in a 1:1 ratio to receive two doses, administered 21 days apart, of either NVX-CoV2373 nanoparticle vaccine (5 µg recombinant spike protein with 50 µg Matrix-M1 adjuvant) or placebo. The primary endpoints were safety and vaccine efficacy ≥7 days following the second dose against laboratory-confirmed symptomatic Covid-19 in previously SARS-CoV-2 uninfected participants.ResultsA total of 4387 participants were randomized and dosed at least once, 2199 with NVX-CoV2373 and 2188 with placebo. Approximately 30% of participants were seropositive at baseline. Among 2684 baseline seronegative participants (94% HIV-negative; 6% PLWH), there were 15 and 29 predominantly mild to moderate Covid-19 cases in NVX-CoV2373 and placebo recipients, respectively; vaccine efficacy was 49.4% (95% confidence interval [CI]: 6.1 to 72.8). Efficacy in HIV-negative participants was 60.1% (95% CI: 19.9 to 80.1), and did not differ by baseline serostatus. Of the primary endpoint cases with available whole genome sequencing, 38 (92.7%) of 41 were the B.1.351 variant. Post-hoc vaccine efficacy against B.1.351 was 51.0% (95% CI: - 0.6 to 76.2) in HIV-negative participants. Among placebo recipients, the incidence of symptomatic Covid-19 was similar in baseline seronegative vs baseline seropositive participants during the first 2 months of follow-up (5.3% vs 5.2%). Preliminary local and systemic reactogenicity were primarily mild to moderate and transient, and higher with NVX-CoV2373; serious adverse events were rare in both groups.ConclusionsThe NVX-CoV2373 vaccine was efficacious in preventing Covid-19, which was predominantly mild to moderate and due to the B.1.351 variant, while evidence of prior infection with the presumptive original SARS-CoV-2 did not confer protection against probable B.1.351 disease. (Funded by Novavax, The Bill and Melinda Gates Foundation, and the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04533399)

Published
2021
Full Text
View/download PDF

7. The impact of participant engagement activities in supporting dapivirine ring use among participants enrolled in the Phase III MTN-020/ASPIRE study

Author

Ariane Van Der Straten, Flavia Matovu Kiweewa, Zakir Gaffoor, Lydia Soto-Torres, Kristine Torjesen, Jared Baeten, Doreen Kemigisha, Leila E. Mansoor, Ellen Luecke, Morgan Garcia, Patrick Ndase, Daniel K. Gondwe, Neetha S. Morar, Yvonne Makala, Kubashni Woeber, Nishanta Singh, Ashley J Mayo, Thesla Palanee-Philips, Krishnaveni Reddy, Nitesha Jeenarain, Petina Musara, and Rachel Scheckter

Subjects
medicine.medical_specialty, Dapivirine, Physical therapy, medicine, Ring (chemistry), Psychology, Phase (combat)
Abstract

Background: Low adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies for at-risk individuals, efforts are needed to improve adherence among study participants. In MTN-020/ASPIRE, a phase III randomized, double-blind, placebo-controlled study of the dapivirine vaginal ring carried out across 15 sites in sub-Saharan Africa, a multifaceted approach to adherence support was implemented, including a strong focus on participant engagement activities (PEAs). In this manuscript, we describe PEAs and participant attendance, and analyze the potential impact of PEAs on ring use. Methods: All sites implemented PEAs and submitted activity and attendance reports to the study management team throughout the study. Participant demographics were collected via case report forms. Ring use was estimated based on residual dapivirine remaining in the last returned ring by each participant and connected to PEA attendance using participant identification numbers. We used multivariate logistic regression to explore differences in ring use between PEA attendance groups and reviewed qualitative reports for illustrative quotes highlighting participant experiences with PEAs. Results: 2,312 of 2,629 study participants attended at least one of 389 PEAs conducted across sites. Participant country and partner knowledge of study participation were most strongly associated with PEA attendance (p < 0.005) with age, education, and income status also associated with event attendance (p < 0.05). When controlling for these variables, participants who attended at least one event were more likely to return a last ring showing at least some use (AOR=3.52) than those who never attended an event. There was an even stronger correlation between a last returned ring showing use and participant attendance at multiple events (AOR=4.03). Conclusions: Our analysis supports the growing body of work illustrating the importance of meaningfully engaging research participants to achieve study success and aligns with other analyses of adherence support efforts during ASPIRE. While causation between PEA attendance and product use cannot be established, residual drug levels in returned rings strongly correlated with participant attendance at PEAs, and the benefits of incorporating PEAs should be considered when designing future studies of investigational products.

Published
2021
Full Text
View/download PDF

8. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study

Author

Jared M Baeten, Thesla Palanee-Phillips, Nyaradzo M Mgodi, Ashley J Mayo, Daniel W Szydlo, Gita Ramjee, Brenda Gati Mirembe, Felix Mhlanga, Portia Hunidzarira, Leila E Mansoor, Samantha Siva, Vaneshree Govender, Bonus Makanani, Logashvari Naidoo, Nishanta Singh, Gonasagrie Nair, Lameck Chinula, Urvi M Parikh, John W Mellors, Iván C Balán, Kenneth Ngure, Ariane van der Straten, Rachel Scheckter, Morgan Garcia, Melissa Peda, Karen Patterson, Edward Livant, Katherine Bunge, Devika Singh, Cindy Jacobson, Yuqing Jiao, Craig W Hendrix, Zvavahera M Chirenje, Clemensia Nakabiito, Taha E Taha, Judith Jones, Kristine Torjesen, Annalene Nel, Zeda Rosenberg, Lydia E Soto-Torres, Sharon L Hillier, Elizabeth R Brown, Dorothy Aanyu, John Abima, Janne Abullarade, Priyanka Agarwal, Surabhi Ahluwalia, Simon Africa Akasiima, Carolyne Agwau Akello, Samuel Albert, Motsamai Alphale, Calins Alphonse, Lucy Apeduno, Sara Aranda, Orly Aridor, Shakeera Arnolds, Prossy Asiimwe, Millicent Atujuna, Didas Atwebembere, Lakshmi Baboolall, Kiran Badana, Jared M. Baeten, David Balamusani, Iván C. Balán, Gabriel Banda, Towera Whitney Banda, Jennifer Baugh, James Amos Baziira, May Beamer, Sivuyisiwe Asanda Bebeza, Linda-Gail Bekker, Ian Bell, Meagan Bemer, Richard Berman, Jennifer Berthiaume, Linda Bezak, Yashveer Bhagwandin, Hassen Anwar Bhayat, Nokulunga Bhengu, Sonto Bhengu, Aruna Bhoola, Florence Asiimwe Biira, Daniel Bittoni, Roberta Black, Nombuso Jacqueline Blose, Pearl Boks, Stephen Gordon Bolton, Phathiswa Botya, Amanda Brown, Elizabeth Brown, Helen Brown, Robyn Helen Bruce, Luke Erismus Bukenya, Aidah Bukirwa, Lisa Bunts, Fezile Buthelezi, Mbongeleni William Buthelezi, Samkelisiwe Dumisile Buthelezi, Rose Byogero, Samiksha Byroo, Robert Byuma, Johanna Albertha Carstens, Allison Carter, Nazneen Cassim, Busisiwe Cebekhulu, Bongekile Cele, Dolly Judith Cele, Phindile Cele, Simangele Cele, Sithabile Cele, Mary Chadza, Nahida Chakhtoura, Claire Chapdu, Gift Tafadzwa Chareka, Charles Chasakara, Manju Chatani-Gada, Diana Chetty, Mary Chidanyika, Tafadzwa Tariro Lisa Chifambi, Emelder Chihota, Sungano Chikono, Anesu Chikonyora, Brett Dzidzai Chikukwa, Craig Chin, Mary Chindevu, Tendai Blessing Chinyanda, Thandiwe Hilda Chirenda, Zvavahera Mike Chirenje, Chiedza Chirisa, Patience Chisale, Angela Chishanga, Tobias Chitambo, Fred Chitema, Flora Chithila, Tinei Helen Chitowa, Catherine Chitsinde, Gladys Chitsulo, Miria Chitukuta, Spiwe Chiveso, Nelecy Chome, Phumelele Fortune Chonco, Emily Christopher, Kerusha Chunderduri, Vutomi Cibi, Naana Cleland, Thobeka Coba, Mandy Rae Cobbing, Clare Collins, Kim Comer, Shameen Cozzi, Danielle Crida, Sufia Dadabhai, Thembakazi Daki, Nwabisa Danster, Reshmi Dassaye, Renita David, Jontraye M. Davis, Sumaya Dawood, Pallabi Deb, Leslie Degnam, Tiffany Sharron Derrick, Bríd Teresa Devlin, Charlene Dezzutti, Patricia Mae Dhlakama, Lorna Dias, Jean Chivoniso Dimairo, Elaine Dinnie, Avile Dlabanta, Msizi Dladla, Thandeka Immaculate Dladla, Andile Princess Dlungele, Curtis Dolezal, Kristine Donaty, Clare Dott, Jenna Dubbs, Vuyiseka Dubula-Majola, Pamella Dukwe, Cebo Ivan Duma, Portia Ignatia Makhosazana Duma, Promise Duma, Vimbai Kudzanai Duncan, Luis Duran, Lindelwa Dyabeni, Andrew Edwards, Radhika Etikala, Juliane Etima, Lee Fairlie, Henry Fischer, Jacqueline Fitzpatrick, Llewellyn Fleurs, Mary Glenn Fowler, Lester Freeman, Zakir Gaffoor, Lizzy Gama, Anita Garg, Vanesa Margret Gatsi, Clifford Gcwensa, Emmanuel Lwandile Gebashe, Samantha Geduld, Jennipher Gelant, Donna Germuga, Joseph Ggita, Rebecca Giguere, Lucy Godo, B. Jay Goetz, Litha Gogo, Esther Goliati, Daniel Kondwani Gondwe, Kelley C. Gordon, Rodney Goreraza, Jayandree Gounden, Dhevium Govender, Justin Sivalingum Govender, Nerusha Govender, Subramonien Govender, Nonkululeko Nosipho Gqwara, Anisa (Tracy) Gravelle, Phindile Guga, Victor Guma, Delisile Zilungile Gumede, Sibusiso Gumede, Thembelihle Gumede, Thobeka Winifred Gumede, Orgrah Gundani, Ravi Gunnam, Rahul Gupta, Mirriam Gwande, Xolani Gxako, Kim Hall, Wayne Hall, Perry Hargrave, Ishana Harkoo, Tanya Harrell, Amy L. Heaps, Simone Lara Hendricks, Craig W. Hendrix, Bongeka Hlabisa, Lungile Bongeka Hlabisa, Kudzai Hlahla, Thulebona Martin Hlela, Thandiwe Hobongwana, Eva Horn, Ridley Howard, Haixiao Huang, Portia Hunidzairia, Nivriti Hurbans, Marla Husnik, Tendai Doreen Hwehwe, Rabia Imamdin, Amina Ismail, Ebrahiema Jacobs, Ashleigh Catherine Jacques, Jane Jamabya, Grace James, Karla Janse van Rensburg, Ziningi Nobuhle Jaya, Nitesha Jeenarain, Lauren Jennings, Haoping Jiang, Ning Jiang, Nwabisa Laurianne Jijana, Godfrey Jokoniya, Mildred Kabasonga, Daniel Kizza Kabenge, Samuel Kabwigu, Evans Kachale, Lonely Kachenjera, Fiona Kachingamire, Emma Kachipapa, Mary Kadiwa, McLoddy Kadyamusuma, Bosco Kafufu, Mary Mukasa Kagwa, Clare Kajura-Manyindo, Brenda Catherine Kakayi, Victoria Kaliwo, Dishiki Jenny Kalonji, Nyasha Elizabeth Kamanga, Betty Kamira, Zerif Kampangire, Getrude Kamwana, Justine Kamya, La-Donna Kapa, Patrick Karugaba, Khumbo Kasambara, Priya Kassim, Sheetal Kassim, Milly Katana, Francis Katongole, Sulaiman Katongole, Alexis Katsis, Chaplain Katumbi, Ariana W.K. Katz, Edmore Kawanje, Caroline Nassozi Kawuma, Sowedi Kayongo, Emily Kekana, Doreen Kemigisha, Siphosihle Khanyile, Nombuso Happiness Khanyisile, Babalwa Khaya, Noluthando Khiya, Norah Ntombikayise Khoza, Thembisile Khumalo, Christina Khwela, Zamo Khwela, Edith Kibiribiri, Ismael Kibirige, Beatrice Kiiza, Florence Sempa Kikonyogo, Melissa Kin, Catherine Kirkwood, Girisha Kistnasami, Flavia Matovu Kiweewa, Max Kiweewa, Deepika Konatham, Lungile Kubheka, Terrence Kufakunesu, Phaleda Kumwenda, Wiza Wisdom Isaac Kumwenda, Maura Kush, Bryan A. Kutner, Ntomboxolo Kwatsha, Rosper Kwedza, Erinah Kyomukama, Debra Lands, Phumelele Nokuthula Langa, Kalkidan Lebeta, Cody Lentz, Brendley Tebogo Leremi, Michelle Leszczewski, Lisa Levy, Ted Livant, Irene Lukas, Lungile Pearl Mabanga, Nomusa Mabaso, Vimbainashe Machisa, Toni M. Maddox, Bernadette Madlala, Nocwaka Magobiane, Melda Magolela, Fungai Maguramhinga, Phumzile Desiree Magwaza, Keshnee Maharaj, Ferial Mahed, Tankiso Vuyiswa Mahlase, Moshukutjoane Lebogang Maila, Yvonne Makala, Patrick Makamure, Kgabo Phineas Makgoka, Pamela Makhamba, Nompumelelo Makhanya, Rulani Makondo, Rujeko Makoni, Henry Makooka, Jennie Makunganya, Sibongile Makwenda, Gakiema Malan, Agnes Malemia, Mariette Malherbe, Faith Malunga, Temantfulini Mamba Nhassengo, Mogau Mampa, Tendai Karen Mamvura, Elmah Manengamambo, Loreen Zandile Mangove, Nomvuyo Thelma Mangxilana, Tsungai Patience Manjera, Winifred Elizabeth Mans, Leila Mansoor, Memory Maoko, Annie Mapfunde, Nonhlanhla Yvonne Maphumulo, Francis E.A. Martinson, Abel Maruwo, Emmerentia Yvonne Marx, Mark A. Marzinke, Moira Masango, Mmathabo Nnana Mashego, Gwendoline Thotele Refilwe Mashinini, Shingirayi Irene Masuko, Kudzai Viviana Matambanadzo, Florence Tintswalo Mathebula, Matheus Mathipa, Jacob Munyaradzi Matsa, Eleanor Agnes Matta, Allen Taguma Matubu, Ayanda Comfort Mavundla, Sandile Mavundla, Billy Mawindo, Josiah Mayani, Emmanuel Mayanja, Nombongo Mayekiso, Nonkululeko Precious Mayisela, Ashley J. Mayo, Mary Speciosa Mbabali, Nonhlakanipho Masibonge Gciniwe Mbanjwa, Constance Seanokeng Mbatha, Nomcedo Janice Mbatha, Dorica Mbewe, Tinkhani Mbichila, Yamikani Rose Mbilizi, Sithokoza Mbokazi, Mwandifitsa Mbwerera, Zethu Mchunu, Laura McKinstry, Bongiwe Mdlongwa, John W. Mellors, Sihle Perfect Meyiwa, Nyaradzo Mavis Mgodi, Erasmus Samuel Mhizha, Nomsa Sibongile Mhlanga, Brenda Gail Mirembe, Dorothy Mirembe, Fumbani Mkandawire, Ntombizethu Hazel Mkhabela, Baningi Mkhize, Princess Hlengiwe Mkhize, Zaba Mkhize, Elizabeth Gugu Mlangeni, Margaret Mlingo, Bukiwe Mngqebisa, Noluxolo Mngxekeza, Anele Mninzi, Nonzwakazi Mnqonywa, Mammekwa Mogkoro, Thembisile Wilmah Mogodiri, Rebone Frengelina Mohuba, Maseponki Cecilia Mokoena, Noxolo Mona, Deidra Montoya, Willie Monyethabeng, Jayajothi Moodley, Jeeva Moodley, Kerushini Moodley, Suri Moonsamy, Neetha Shagan Morar, Sophie Nomsa Morudu, Angela Mpekula, Gerald Thsepo Mphisa, Jayne Mpofu, Hlengiwe Theodora Mposula, Avril Mqadi, Emmie Msiska, Lusungu Msumba, Nana Mtambo, Emmanuel Sinothi Mthalane, Thabisile Susan Mthembu, Zanoxolo Mthethi, Magdeline Judith Mthethwa, Ntokozo Zabathethwa Mthethwa, Sicelo Samuel Mthimkhulu, Itsepheng Mtlokoa, Michael Charles Mubiru, Mary Mudavanhu, Anna Zvirevo Mufumisi, Agnes Mary Mugagga, Joanita Muganga, Michelle Mugava, Margaret Mugenyi, Caroline Mugocha, Faith Mugodhi, Norma Mugwagwa, Felix Godwin Sivhukile Muhlanga, Shorai Mukaka, Dick Mukasa, Restituta Mukasa, Mathews Mukatipa, Shedina Mukova, Sarah Mulebeke, Joyce Mulima, Julio Muller, Faith Mulumba, Tsitsi Mupamombe, Constance Murandu, Tarisai Murefu, Fungai Murewa, Kudakwashe Muringayi, Caroline Murombedzi, Petina Musara, Jane Nsubuga Musisi, Mary Maria Musisi, Philippa Musoke, Joseph Mutebo, Prisca Mutero, Kudzai Santana Mutiti, Shadreck Mutizira, Sharon Mutsvunguma, Netsai Muungani, Tariro Muvunzi, Rosemary Muwawu, Samkelisiwe Mvelase, Priscilla Pamela Mvinjelwa, Goodness Zoh Mvuyane, Liness Mwafulirwa, Pokiwe Mwagomba, Thoko Gift Mwakhwawa, Deborah Mwebaza, Wezi Longwe Mwenda, Nqobile Myeni, Angeline Doreen Nonhlanhla Mzolo, Regina Bukenya Nabatanzi, Joselyne Nabisere, Josephine Nabukeera, Christine Valerie Nagawa, Cherise Naicker, Kumari Naicker, Vimla Naicker, Ishana Naidoo, Jason Naidoo, Jayganthie Naidoo, Kalendri Naidoo, Renissa Naidoo, Sandy Naidoo, Nalini Naidu, Gonasagrie Lulu Nair, Susan Nakacwa, Joyce Gladys Nakakande, Rita Nakalega, Maria Gorreti Nakalema, Jesca Nakibuka, Teopista Nakyanzi, Justine Nakyeyune, Stella Nalusiba, Rhoda Namakula, Felix Namalueso, Paula Mubiru Namayanja, Christine Tapuwa Nampala, Suzan Nkalubo Nampiira, Agnes Namuddu, Norah Nandundu, Winnie Nansamba, Stella Nanyonga, Sophie Clare Nanziri, Zainab Nakivumbi Nassoma, Duduzile Ethel Ncube, Eva Ncube, Sithabile Ncube, Pepukayi Ndadziyira, Pamella Pumla Ndamase, Walter Seth Taurayi Nderecha, Zanele Ndhlovu-Forde, Thembelihle Cynthia Ndimande, Bukekile Ndlovu, Grecenia Ndlovu, James Ndlovu, Nontokozo Happiness Ndlovu, Thakisile Nontokozo Ndlovu, Zodwa Ndlovu, Margret Ndovie, Beauty Nemasango, Blazej Neradilek, Susan Ngani, Nokwanda Queeneth Ngcebethsha, Lizbon Ngcobela, Nolwazi Ngcobo, Nompumelelo Ngcobo, Sindisiwe Promise Ngcobo, Nidleka Ngcukana, Julie Ngo, Nontshukumo Ngqabe, Siyabonga Ngqame, Mduduzi Dawood Ngubane, Nancy Nokuthula Ngwenya, Mugowe Nhkoma, Bongiwe Ntombizodwa Nhlapho, Sibusiso Nhleko, Hlengiwe Nkwanyana, Heather Noble, Lumka Lucia Nobula, Monica Nolan, Mluleki Nompondwana, Busiwe Notshokovu, Vukani Sandile Ntanzi, Nishi Nursaye, Jeremy Peter Nutall, Omega Nyabadza, Evelesi Nyaka, Sandra Nyakudya, Envioletta Chiedza Nyakura, Shingayi Nyamadzawo, Tsitsi Nyamuzihwa, Zubayiri Nyanzi, Angel Tinny Nyathi, Fadire Nyirenda, Makandwe Nyirenda, Mary Nyirenda, Sinqobile Charity Nzama, Lamec Sbongisomi Nzuza, Bhavesha O'Byrne, Fabian Okello, Eunice Okumu, Emmanuel Oluka, Francis Onen, Carolyne Peris Onyango, Katherine Ostbye, Kerusha Padayachee, Victor Palichina, Zhenyu Pan, Colin Pappajohn, Levanya Paramanund, Urvi M. Parikh, Nazmie Pearce, Kerri J. Penrose, Bathandekile Molly Phahlamohlaka, Nokulunga Ruth Phidane, Omisha Pillay, Anamika Premrajh, Nikita Prosad, Lorna Rabe, Alishka Rajman, Keneoe Maphuti Rampai, Hlalifi Sylvia Rampyapedi, April Randhawa, Sabelo Rasmeni, Dianne Rausch, Avanita Reddy, Isayum Reddy, Jerusha Reddy, Krishnaveni Reddy, Vera Helen Rees, Andrea Repetto, Cheryl Richards, Sharon Riddler, Nobubele Rini, Brendon Roeber, Lisa Rohan, Zachary Romer, Matthew Rose, Zeda Fran Rosenberg, Lisa Rossi, Aviva Ruch, Christine Rullo, Sinazo Runeyi, Olivia Rupemba, Chenai Rushwaya, Marisa Russell, Patience Sharai Ruzive, Godfrey Rwanzogyera, Margaret Nakato Saava, Tshepo Jimmy Sagela, Rebecca Sakwa, Fathima Sayed, Jennifer Schille, Nokwayintombi Scotch, William Scott, Caitlin Scoville, Richard Sebagala, Elaine Sebastian, Natasha Tina Sedze, Nasreen Hoosen Seedat, Joseph Semakula, Teri Senn, Francis Serugo, Linly Seyama, Bhekanani Khumulani Shabalala, Charlotte Phumzile Shangase, Pamela Caroline Shanhinga, Jeremy Shaver, Hanjie Shen, Mogobalale Corlett Shogole, Rachel Shonhiwa, Claudia Shozi, Marvelous Sibanda, Sylvia Sibongile Sibeko, Ncamisile Teressa Sibisi, Samuel Siphelele Sibisi, Brighty Zweni Sibiya, Happiness Sibiya, Dorothy Sichali, Phumzile Yvonne Sikosana, Craig Silva, Ayanda Purity Simelane, Melissa Simon, Triesha Sing, Hailey Virginia Sithole, Edith Sitima, Alex Siyasiya, Vuyane Sizane, Bekezela Siziba, Edward Slezinger, Daria Smolinski, Katie Snapinn, Olwethu Sogoni, Dean Soko, Leonard Nichiren Solai, Mandiphumle Somga, Mei Song, Xiaoling Song, Devarani Soobryan, Lydia Soto-Torres, Patrick Lawrence Spence, Elizabeth Spooner, Vincent Sseguya, Augustine Ssentongo, Mark Ssenyonga, Lawrence Lollian Sseremba, Michael Stais, John Steytler, Sharon Stockton, Julie Stofel, Tinyiko Reginah Stuurman, Sizakele Sukazi, Jasmin Lynn Sukdao, Kranthi Swarna, Daniel Szydlo, Christine Tagliaferri Rael, Dorothy Rumbidzai Taguta, Taha Taha, Eunice Tahuringana, Joshua Tamale, Penelope Tambama, Edna Taulo, Frank Taulo, Thelma Tonderai Tauya, Gerald Tegha, Sindisiwe Lucia Tembe, Tchangani Tembo, Constance Lebo Thatelo, Pinky Mery Thobela, Annie Thom, Christine Thompson, Monica Thompson, Linda Thusi, Lauri Tock, Thandokazi Tofile, Carol Tranfaglia, Jenny Tseng, Themba Tshabalala, Nomvuselelo Tshongoyi, Mercy Tsidya, Wendy Rufaro Tsikiwa, NoCamagu Tuswa-Haynes, Bomkazi Onini Tutshana, Andile Premrose Twala, Ashvir Viren Udith, Christine Unten, Neliette van Niekerk, Amanda Varela, Nangamso Vatsha, Gayathri Vijayendran, Amukelani California Vuma, Deo Ogema Wabwire, Madalo Walani, Bhekisisa Wanda, Lisa Wasberg, Rhonda R. White, Kathleen Marie Windle, Kubashni Woeber, Danica Wright, Tiffanee Wright, Thembalethu Nontokozo Xaba, Makanaka Jean Savie Yambira, Ntando Yola, Sindisiwe Lydia Zaca, Aisha Zalwango, Jullian Zemanek, Chifundo Zimba, Tsitsi Zinyengere, Margaret Zinyongo, Thabile Goodness Zondi, Chun Zou, Jabulisile Zuma, Nokuthula Princess Zungu, and Nompumelelo Zungu

Subjects
0301 basic medicine, Adult, Zimbabwe, medicine.medical_specialty, Malawi, Epidemiology, Anti-HIV Agents, Immunology, Dapivirine, HIV Infections, Placebo, Article, 03 medical and health sciences, South Africa, 0302 clinical medicine, Virology, Internal medicine, Microbicide, medicine, Humans, Uganda, 030212 general & internal medicine, Tenofovir, business.industry, Surrogate endpoint, Incidence (epidemiology), Contraceptive Devices, Female, 030112 virology, Vaginal ring, Clinical trial, Administration, Intravaginal, Infectious Diseases, Clinical research, Pyrimidines, Treatment Outcome, Seroconversion, HIV-1, Patient Compliance, Female, Patient Safety, business
Abstract

Two phase 3 clinical trials showed that use of a monthly vaginal ring containing 25 mg dapivirine was well tolerated and reduced HIV-1 incidence in women by approximately 30% compared with placebo. We aimed to evaluate use and safety of the dapivirine vaginal ring (DVR) in open-label settings with high background rates of HIV-1 infection, an important step for future implementation.We did a phase 3B open-label extension trial of the DVR (MTN-025/HIV Open-label Prevention Extension [HOPE]). Women who were HIV-1-negative and had participated in the MTN-020/ASPIRE phase 3 trial were offered 12 months of access to the DVR at 14 clinical research centres in Malawi, South Africa, Uganda, and Zimbabwe. At each visit (monthly for 3 months, then once every 3 months), women chose whether or not to accept the offer of the ring. Used, returned rings were tested for residual amounts of dapivirine as a surrogate marker for adherence. HIV-1 serological testing was done at each visit. Dapivirine amounts in returned rings and HIV-1 incidence were compared with data from the ASPIRE trial, and safety was assessed. This study is registered with ClinicalTrials.gov, NCT02858037.Between July 16, 2016, and Oct 10, 2018, of 1756 women assessed for eligibility, 1456 were enrolled and participated in the study. Median age was 31 years (IQR 27-37). At baseline, 1342 (92·2%) women chose to take the DVR; ring acceptance was more than 79% at each visit up until 12 months and 936 (73·2%) of 1279 chose to take the ring at all visits. 12 530 (89·3%) of 14 034 returned rings had residual dapivirine amounts consistent with some use during the previous month (0·9 mg released) and the mean dapivirine amount released was greater than in the ASPIRE trial (by 0·21 mg; p0·0001). HIV-1 incidence was 2·7 per 100 person-years (95% CI 1·9-3·8, 35 infections), compared with an expected incidence of 4·4 per 100 person-years (3·2-5·8) among a population matched on age, site, and presence of a sexually transmitted infection from the placebo group of ASPIRE. No serious adverse events or grade 3 or higher adverse events observed were assessed as related to the DVR.High uptake and persistent use in this open-label extension study support the DVR as an HIV-1 prevention option for women. With an increasing number of HIV-1 prophylaxis choices on the horizon, these results suggest that the DVR will be an acceptable and practical option for women in Africa.The Microbicide Trials Network and the National Institute of Allergy and Infectious Diseases, The Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health, all components of the US National Institutes of Health.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results